Momecutan (Mometasone Furoate Ph. Eur.)

Mometasone furoate binds to glucocorticoid receptors in skin cells, altering gene expression to suppress pro‑inflammatory cytokines, inhibit leukocyte migration, and reduce vascular permeability. This results in potent local anti‑inflammatory and immunosuppressive activity.

The appropriate amount and frequency of Momecutan are determined by the prescribing healthcare professional based on the specific condition, severity, patient age and treatment area. Patients should follow the prescriber's instructions precisely.

Safety data for topical mometasone furoate in pregnancy or lactation are limited. Healthcare providers should weigh potential benefits against risks and consider alternative therapies when appropriate. Women should discuss use with their obstetrician or pediatrician.

To request Momecutan, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Momecutan contains mometasone furoate, a high‑potency corticosteroid offering strong anti‑inflammatory effects with a favorable safety profile when used as directed. Compared with lower‑potency agents, it may achieve faster symptom control but requires careful monitoring to avoid local adverse effects.

Store Momecutan at room temperature, below 25 °C, in the original packaging. Keep it away from moisture, excessive heat and direct sunlight to maintain product stability.

Momecutan is applied topically to the affected skin area in a thin layer, usually once or twice daily as instructed by the prescriber. Hands should be washed before and after application, and the treated area should be gently rubbed in until absorbed.

Serious risks include skin atrophy, secondary infections, adrenal suppression with extensive use, and rare systemic effects such as Cushingoid features. Patients should report any unusual skin changes, signs of infection or systemic symptoms to their healthcare provider promptly.

Momecutan should be avoided in individuals with known hypersensitivity to mometasone furoate or any formulation components, in patients with untreated skin infections at the application site, and in those where systemic corticosteroid exposure is contraindicated unless directed by a physician.